To evsluate the elinical significance of UFT-cisplatin neoadjuvant chemotherapy in patients with locally advanced cervical cancer, we compared the response rate and the toxicity of UFT-cisplatin(UFT- P) ehemotherapy with those of 5-FU, cisplatin(FP) cheniotherapy, Between January 1989 and February 1993, 21 patients with locally advanced cervical carcinoma(FIGO stages ItrI~lb) initially were treated with two or three courses of UFT-cisplatin neoadjuvant chemotherapy and 22 patients were treated with FP neoadjuvant chemotherapy. The results were obtained as follows. 1. The clinical response rate to UFT-P chemotherapy(overall; 81.0%, complete response; 4.8%, partial response; 76.2%) was higher than FP chemotherapy( overall; 59.1%, partial response; 59.1%), but there was no statistieal differenee(p=0.185). 2. There were no significant differenee between UFT-P and FP chemotherapy according to the post-operative pathologie results(cervieal involvement, parametriurn invo)vement, resection margin, lymph node metastasis, lymphovascular spaee inv 3. There were higher incidence of granuloctopenia and diarrhea in UFT-P chemotherapy than FP chemotherapy, So these data suggest that UFT-P neoadjuvant chemotherapy may be clinically useful as a neoadjuvant chemotherapy in uterine cervical carcincma due to its high response rate, short hospitalization day and convinience of administration. But the toxieity, granulocytopenia and diarrhea was relatively higher than FF neoadjuvant chemotherapy.